



\*\*\*\*\*  
**Dr. Emanuele Boero**

Huvepharma Italia

Via Roberto Lepetit 142 - 12075 Garessio (CN)

emanuele.boero@huvepharma.com



### **CV**

Business and R&D Director of Huvepharma Italia, a company which develops and manufactures active drug substances, cosmetic substances and nutraceuticals.

Graduated (BS/MS) in Industrial Chemistry from the University of Genoa in 1995 he has over 20 years of experience in APIs industries mostly spent in Sanofi but also including GSK and Teva with different roles such as: senior scientist in process development, manager of quality control, production manager, CDMO site director, QP and head of quality and regulatory.

He participated in several development and industrialization projects of small molecules with novel technologies and significant scaling-up challenges.

**Tuesday, April 23<sup>rd</sup> 2024**

**Polo didattico Alberti**

**via L.B. Alberti 4**

**Aula 2**

**ore 11**

**A type Course**

***Developing a new drug: business decision making and industrialization of a medicinal chemistry process***

### **Abstract**

The pharmaceutical industry is a highly diverse sector, encompassing large multinational corporations, innovative biotechnological startups, and specialized service providers. Central to this industry is the mission to discover, develop, produce, and market drugs, with patients as the ultimate beneficiaries.

The development of new pharmaceuticals is an expensive and time-intensive endeavor, laden with high risks. Despite extensive R&D efforts, only a fraction of drugs under development reaches the market, underscoring the high-stakes nature of pharmaceutical innovation.

Operational considerations are also pivotal, including the development and validation of manufacturing processes, capital investments in equipment, and the management of manufacturing and distribution costs.

This lecture aims to shed light on the financial considerations, risks, and opportunities inherent in the pharmaceutical sector, offering insights into the decision-making processes that guide companies in their pursuit of innovation and market success.

Main topics covered include the escalating costs of drug development, the intricacies of process development, and the economics of manufacturing pharmaceutical products.